FIELD: medicine.
SUBSTANCE: invention relates to a nitrogen-containing heterocyclic compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof: 
where Z1 is N or CR6; X1 is NR9 or S; R2 is a hydrogen or a halogen atom; R3 represents a hydrogen atom or a halogen atom; R4 represents a hydrogen atom, a halogen atom, an amino group or a C1-6alkoxy group; the values of the remaining substituents are indicated in the claims. Invention also relates to a nitrogen-containing heterocyclic compound of the formula [1a], to a remedy for a disease treatment in which inhibition of PI3K and / or ERK is effective, to a PI3K and / or ERK inhibitor and to individual nitrogen-containing heterocyclic compounds.
EFFECT: technical result: new compounds having inhibitory activity against PI3K and / or ERK were obtained.
19 cl, 10 tbl, 995 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRKA KINASE INHIBITORS, COMPOSITIONS BASED THEREON AND METHODS | 2015 |
|
RU2672583C2 |
| HETEROCYCLIC COMPOUNDS FOR TYROSINE KINASE 2 ACTIVITY MEDIATION | 2020 |
|
RU2826012C2 |
| AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
| CDK4/6 INHIBITOR | 2017 |
|
RU2747311C2 |
| NEW NICOTINAMIDE DERIVATIVE OR SALT THEREOF | 2011 |
|
RU2560163C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| NOVEL IMIDAZOOXAZINE COMPOUND OR SALT THEREOF | 2012 |
|
RU2578608C2 |
| SUBSTITUTED AMINO SIX-MEMBER SATURATED HETEROALICYCLES AS LONG-ACTING DPP-IV INHIBITORS | 2016 |
|
RU2720488C2 |
| USE OF 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | 2017 |
|
RU2759380C2 |
| SPIRO COMPOUNDS AS ANTAGONISTS OF MELANOCORTIN 4 RECEPTORS AND THEIR USE | 2021 |
|
RU2813541C1 |
